BACKGROUND/AIMS: In adults, plasma exchange (PE) has been shown to be an efficient treatment for severe relapses of acute inflammatory CNS demyelinating diseases. The aim of this study was to evaluate the safety and efficacy of this treatment in pediatric patients. METHODS: We retrospectively analyzed a single-center cohort of pediatric patients with inflammatory CNS demyelinating disorders who underwent apheresis between 2007 and 2011. RESULTS: Ten patients (mean age: 11.6 ± 3.4 years) with an acute relapse of multiple sclerosis (n = 5), neuromyelitis optica (n = 2) or acute disseminated encephalomyelitis were included. All received methylprednisolone prior to treatment with either PE (n = 5) or immunoadsorption (n = 5). Apheresis-related side effects were either self-limiting or easily managed. EDSS (Expanded Disability Status Scale) improved in 7 of 8 patients during apheresis and in all patients within 30 days from a median of 7.5 to 1 (p < 0.01). The visual acuity initially worsened during the procedure in 3 of 7 affected eyes (mean 0.09), but improved in all at follow-up (mean: 0.5; p = 0.008). CONCLUSIONS: Apheresis was well tolerated and associated with a favorable outcome in all pediatric patients similar to reports in adults.
BACKGROUND/AIMS: In adults, plasma exchange (PE) has been shown to be an efficient treatment for severe relapses of acute inflammatory CNS demyelinating diseases. The aim of this study was to evaluate the safety and efficacy of this treatment in pediatric patients. METHODS: We retrospectively analyzed a single-center cohort of pediatric patients with inflammatory CNS demyelinating disorders who underwent apheresis between 2007 and 2011. RESULTS: Ten patients (mean age: 11.6 ± 3.4 years) with an acute relapse of multiple sclerosis (n = 5), neuromyelitis optica (n = 2) or acute disseminated encephalomyelitis were included. All received methylprednisolone prior to treatment with either PE (n = 5) or immunoadsorption (n = 5). Apheresis-related side effects were either self-limiting or easily managed. EDSS (Expanded Disability Status Scale) improved in 7 of 8 patients during apheresis and in all patients within 30 days from a median of 7.5 to 1 (p < 0.01). The visual acuity initially worsened during the procedure in 3 of 7 affected eyes (mean 0.09), but improved in all at follow-up (mean: 0.5; p = 0.008). CONCLUSIONS: Apheresis was well tolerated and associated with a favorable outcome in all pediatric patients similar to reports in adults.
Authors: F Hoffmann; A Kraft; F Heigl; E Mauch; J Koehler; L Harms; T Kümpfel; W Köhler; R Klingel; C Fassbender; S Schimrigk Journal: Nervenarzt Date: 2015-02 Impact factor: 1.214
Authors: Leoni Rolfes; Steffen Pfeuffer; Tobias Ruck; Nico Melzer; Marc Pawlitzki; Michael Heming; Marcus Brand; Heinz Wiendl; Sven G Meuth Journal: J Clin Med Date: 2019-10-04 Impact factor: 4.241
Authors: Frank Hoffmann; Andrea Kraft; Franz Heigl; Erich Mauch; Jürgen Koehler; Lutz Harms; Tania Kümpfel; Wolfgang Köhler; Sven Ehrlich; Antonios Bayas; Julia Weinmann-Menke; Carolin Beuker; Karl-Heinz Henn; Ilya Ayzenberg; Gisa Ellrichmann; Kerstin Hellwig; Reinhard Klingel; Cordula Marie Fassbender; Harald Fritz; Torsten Slowinski; Horst Weihprecht; Marcus Brand; Thomas Stiegler; Jan Galle; Sebastian Schimrigk Journal: Ther Adv Neurol Disord Date: 2018-05-28 Impact factor: 6.570
Authors: Ingo Kleiter; Anna Gahlen; Nadja Borisow; Katrin Fischer; Klaus-Dieter Wernecke; Kerstin Hellwig; Florence Pache; Klemens Ruprecht; Joachim Havla; Tania Kümpfel; Orhan Aktas; Hans-Peter Hartung; Marius Ringelstein; Christian Geis; Christoph Kleinschnitz; Achim Berthele; Bernhard Hemmer; Klemens Angstwurm; Jan-Patrick Stellmann; Simon Schuster; Martin Stangel; Florian Lauda; Hayrettin Tumani; Christoph Mayer; Markus Krumbholz; Lena Zeltner; Ulf Ziemann; Ralf Linker; Matthias Schwab; Martin Marziniak; Florian Then Bergh; Ulrich Hofstadt-van Oy; Oliver Neuhaus; Uwe K Zettl; Jürgen Faiss; Brigitte Wildemann; Friedemann Paul; Sven Jarius; Corinna Trebst Journal: Neurol Neuroimmunol Neuroinflamm Date: 2018-09-26